Table 1 Characteristics of the study participants
Characteristic | No. of patients, N = 146 |
|---|---|
SLE, no. (%) | 121 (82.80) |
RA, no. (%) | 25 (17.20) |
Age, mean ± SD years | 42.27 ± 14.13 |
Female, no. (%) | 139 (95.20) |
Weight, mean ± SD kg | 56.89 ± 9.21 |
Duration of HCQ treatment, mean ± SD months | 51.70 ± 46.50 |
HCQ dose, mean ± SD mg/day | 255.48 ± 77.93 |
HCQ dose, mean ± SD mg/kg/day | 4.58 ± 1.50 |
Daily prednisolone dose, mean ± SD mg | 4.77 ± 4.33 |
DSA28 score, mean ± SD | 2.16 ± 0.41 |
SLEDAI score, mean ± SD | 0.89 ± 1.81 |
[HCQ], mean ± SD ng/ml | 838.10 ± 522.00 |
[DHCQ], mean ± SD ng/ml | 582.80 ± 363.90 |
[DCQ], mean ± SD ng/ml | 346.90 ± 205.30 |
[BDCQ], mean ± SD ng/ml | 56.00 ± 39.30 |
ADR, no. (%) | |
Abnormal renal function | 21 (14.30) |
Abnormal liver function | 11 (7.50) |
Ophthalmic ADRs | 20 (13.70) |
Skin and mucous membrane ADRs | 15 (10.30) |